NellOne Therapeutics

About:

NellOne Therapeutics develops Nell1 protein therapeutics for restoring tissue mass and function in patients recovering from heart attacks.

Website: http://www.nell-one.com

Top Investors: National Science Foundation, Launch Tennessee, Battelle Ventures, Innovation Valley Partners

Description:

NellOne Therapeutics is a regenerative medicine company that has been spun out of the U.S. Department of Energy's Oak Ridge National Laboratory in Oak Ridge, Tenn. Senior Staff Scientist Dr. Cymbeline Culiat in the Lab's Biosciences Division / Systems Genetics Group had identified the activity of the Nell1 gene's pathway in the formation of key mammalian tissues and organs, and Battelle Ventures founded NellOne to translate her basic science discovery into clinical applications. The company is dedicated to developing and commercializing Nell1 protein therapeutics for restoring tissue mass and function in patients recovering from heart attacks.

Total Funding Amount:

$1.74M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Knoxville, Tennessee, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)nell-one.com

Founders:

Cymbeline Culiat, Tracy Warren

Number of Employees:

1-10

Last Funding Date:

2021-09-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai